Product quality considerations for cellular and gene therapy products
RF QuarterlyAmanda Lee, PhD, RAC
Advanced therapies/cell and gene therapyComplianceEuropeEuropean Medicines Agency (EMA)Product developmentProduct LifecycleQuality Assurance and ControlUnited StatesUS Food and Drug Administration (FDA)